 | Up a level |
Abken, H. (2017). The fourth generation of CARs: TRUCKs can activate the innate response towards tumors. Transfus. Med. Hemother., 44. S. 28 - 29. BASEL: KARGER. ISSN 1660-3818
Alzubi, J., Dettmer, V., Kuehle, J., Seidl, M., Taromi, S., Zeiser, R., Abken, H., Cathomen, T. and Wolf, P. (2018). A novel chimeric antigen receptor CAR-T cell approach eliminates prostate cancer in a mouse tumour model. Hum. Gene Ther., 29 (12). S. A21 - 1. NEW ROCHELLE: MARY ANN LIEBERT, INC. ISSN 1557-7422
Berger, A., Weber, I., Khan, S., Chiemlewski, M., Abken, H., Theobald, M. and Hartwig, U. F. (2016). GENERATION OF CHIMERIC ANTIGEN RECEPTOR - MODIFIED MEMORY STEM CELL CD8+T LYMPHOCYTES FROM NAIVE PRECURSORS BY MODULATION OF WNT/BETA-CATENIN PATHWAY OR INHIBITION OF AKT-SIGNALING. Haematologica, 101. S. 192 - 193. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Faitschuk, E., Nagy, V., Hombach, A. A. and Abken, H. (2016). A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv. Gene Ther., 23 (10). S. 718 - 727. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5462
Festag, M., Wisskirchen, K., Hasreiter, J., Schreiber, S., Abken, H. and Protzer, U. (2018). EVALUATION OF A FULLY HUMAN CAR FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION IN AN IMMUNOCOMPETENT MOUSE MODEL. Hum. Gene Ther., 29 (11). S. A4 - 1. NEW ROCHELLE: MARY ANN LIEBERT, INC. ISSN 1557-7422
Hartwig, U. F., Berger, A., Weber, I, Khan, S. A., Chmielewski, M., Abken, H. and Theobald, M. (2016). CD19 CAR-redirected memory stem cell and central memory T lymphocytes generated from naive T cell precursors by inhibition of Akt-signaling induce potent antitumor immunity. Oncol. Res. Treat., 39. S. 314 - 316. BASEL: KARGER. ISSN 2296-5262
Hombach, A., Hombach, A. A. and Abken, H. (2010). Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther., 17 (10). S. 1206 - 1214. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5462
Kobold, S., Steffen, J., Chaloupka, M., Grassmann, S., Henkel, J., Castoldi, R., Zeng, Y., Chmielewski, M., Schmollinger, J., Schnurr, M., Rothenfusser, S., Schendel, D. J., Abken, H., Sustmann, C., Niederfellner, G., Klein, C., Bourquin, C. and Endres, S. (2014). Bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. Oncol. Res. Treat., 37. S. 239 - 240. BASEL: KARGER. ISSN 2296-5262
Krebs, K., Boettinger, N., Huang, L., Chmielewski, M., Uckert, W., Abken, H., Heikenwaelder, M., Knolle, P. and Protzer, U. (2014). T CELLS REDIRECTED BY A CHIMERIC ANTIGEN RECEPTOR RECOGNIZING HBSAG EFFICIENTLY CONTROL HBV IN VIVO IN TRANSGENIC MICE. Cytotherapy, 16 (4). S. S9 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1477-2566
Krug, C., Saenger, B., Chmielewski, M., Birkholz, K., Schwenkert, M., Fey, G., Schuler, G., Abken, H., Doerrie, J. and Schaft, N. (2014). The influence of binding affinity and receptor density of chimeric antigen receptors on target-cell recognition after transfer by RNA electroporation. Exp. Dermatol., 23 (3). S. E25 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Kuehle, J., Hofmann, P., Chmielewski, M. and Abken, H. (2017). T cell-directed enzyme-prodrug therapy (TDEPT): CAR T cells engineered for tumour-restricted activation of cytotoxic prodrugs. Hum. Gene Ther., 28 (12). S. A38 - 1. NEW ROCHELLE: MARY ANN LIEBERT, INC. ISSN 1557-7422
Kunert, A., Chmielewski, M., Wijers, R., Berrevoets, C., Abken, H. and Debets, R. (2018). Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. OncoImmunology, 7 (1). PHILADELPHIA: TAYLOR & FRANCIS INC. ISSN 2162-402X
Meyer, J., Meyer, J., Morgan, M., Falk, C. S., Abken, H., Schambach, A. and Galla, M. (2017). Efficient killing of target cells in vitro by transiently engineered chimeric antigen receptor expressing NK cells. Hum. Gene Ther., 28 (12). S. A26 - 1. NEW ROCHELLE: MARY ANN LIEBERT, INC. ISSN 1557-7422
Oberbeck, S., Schrader, A., Warner, K., Jungherz, D., Crispatzu, G., von Jan, J., Chmielewski, M., Ianevski, A., Diebner, H. H., Mayer, P., Ados, A. Kondo, Wahnschaffe, L., Braun, T., Mueller, T. A., Wagle, P., Bouska, A., Neumann, T., Puetzer, S., Varghese, L., Pflug, N., Thelen, M., Makalowski, J., Riet, N., Goex, H. J. M., Rappl, G., Altmueller, J., Kotrova, M., Persigehl, T., Hopfinger, G., Hansmann, M. L., Schloesser, H., Stilgenbauer, S., Duerig, J., Mougiakakos, D., Von Bergwelt-Baildon, M., Roeder, I, Hartmann, S., Hallek, M., Moriggl, R., Brueggemann, M., Aittokallio, T., Iqbal, J., Newrzela, S., Abken, H. and Herling, M. (2020). Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. Blood, 136 (24). S. 2786 - 2803. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Rengstl, B., Hartmann, S., Eberth, S., Doering, C., Pommerenke, C., Becker, P. S. A., Weiser, C., Warner, K., Doering, C., Seidl, C., Kueppers, R., Abken, H., MacLeod, R. A., Drexler, H. G., Hansmann, M. -L. and Newrzela, S. (2016). SIP-F1: A NEW GRAY ZONE LYMPHOMA CELL LINE? Haematologica, 101. S. 9 - 11. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Rengstl, B., Schmid, F., Weiser, C., Doering, C., Heinrich, T., Warner, K., Becker, P. S. A., Wistinghausen, R., Kameh-Var, S., Werling, E., Billmeier, A., Seidl, C., Hartmann, S., Abken, H., Kueppers, R., Hansmann, M. -L. and Newrzela, S. (2016). TUMOR INFILTRATING HLA-MATCHED CD4+T CELLS RETARGETED AGAINST HODGKIN AND REED-STERNBERG CELLS. Haematologica, 101. S. 30 - 31. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Schirmer, D., Storz, I., Wisskirchen, K., Feederle, R., Schmidt, O., Abken, H., Protzer, U., Burdach, S. and Richter, G. (2018). GPR64-specific CAR-trnasgenic T cells selectively kill Ewing sarcoma cells. Oncol. Res. Treat., 41. S. 130 - 131. BASEL: KARGER. ISSN 2296-5262
Schlaak, M., Schmidt, P., Bangard, C., Kurschat, P., Mauch, C. and Abken, H. (2012). Current Therapeutic approaches in the Treatment of metastatic malignant Melanoma. J. Dtsch. Dermatol. Ges., 10 (11). S. 858 - 860. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0379
Simon-Keller, K., Paschen, A., Eichmueller, S., Gattenloehner, S., Barth, S., Koscielniak, E., Leuschner, I., Stoebel, P., Hombach, A., Abken, H. and Marx, A. (2010). Adoptive T-cell therapy of rhabdomyosarcoma. Pathologe, 31. S. 215 - 221. NEW YORK: SPRINGER. ISSN 0172-8113
Szoor, A., Holzinger, A., Pham, A., Abken, H. and Vereb, G. (2018). SURFACE MOBILITY AND CLUSTER FORMATION OF VARIOUS MELANOMA ASSOCIATED ANTIGENS MODULATES CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELL ACTIVATION. Hum. Gene Ther., 29 (11). S. A12 - 1. NEW ROCHELLE: MARY ANN LIEBERT, INC. ISSN 1557-7422
Thomalla, D., Beckmann, L., Grimm, C., Oliverio, M., Meder, L., Herling, C. D., Nieper, P., Feldmann, T., Merkel, O., Lorsy, E., Guerreiro, A. da Palma, von Jan, J., Kisis, I., Wasserburger, E., Claasen, J., Faitschuk-Meyer, E., Altmueller, J., Nuernberg, P., Yang, T. -P., Lienhard, M., Herwig, R., Kreuzer, K. -A., Pallasch, C. P., Buettner, R., Schaefer, S. C., Hartley, J., Abken, H., Peifer, M., Kashkar, H., Knittel, G., Eichhorst, B., Ullrich, R. T., Herling, M., Reinhardt, H. C., Hallek, M., Schweiger, M. R. and Frenzel, L. P. (2022). Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood, 140 (20). S. 2113 - 2127. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020